Phosphotyrosine phosphatase activity in the macrophage is enhanced by lipopolysaccharide, tumor necrosis factor α, and granulocyte/macrophage-colony stimulating factor: correlation with priming of the respiratory burst  by Bassal, Sahar et al.
 .Biochimica et Biophysica Acta 1355 1997 343–352
Phosphotyrosine phosphatase activity in the macrophage is enhanced by
lipopolysaccharide, tumor necrosis factor a , and
granulocytermacrophage-colony stimulating factor: correlation with
priming of the respiratory burst
Sahar Bassal, Yong Shu Liu, Robert J.S. Thomas, Wayne A. Phillips )
Uni˝ersity of Melbourne Department of Surgery, Western Hospital, Footscray, Vic. 3011, Australia
Received 10 July 1996; revised 20 September 1996; accepted 26 September 1996
Abstract
Tyrosine phosphorylation is now recognised as a key event in the activation of the macrophage respiratory burst. Since
 .vanadate, a phosphotyrosine phosphatase PTP inhibitor is able to enhance the respiratory burst, we proposed that agents
which prime the macrophage for enhance respiratory burst activity may do so by suppressing cellular PTP activity. The
 .level of PTP activity in murine bone marrow-derived macrophages BMM was assessed by the ability of cell lysates to
dephosphorylate 32 P-labelled RR-src peptide. In contrast to our hypothesis, pretreatment of BMM with bacterial lipopoly-
 .  .  .saccharide LPS , tumor necrosis factor a TNFa or granulocytermacrophage-colony stimulating factor GMCSF , agents
which prime for enhanced respiratory burst activity, was found to dramatically increase the level of cellular PTP activity.
The time-course for this increase correlated well with the time course of priming by these agents. In addition, colony
stimulating factor-1, a cytokine which does not prime the macrophage respiratory burst, did not enhance PTP levels. The
physiological relevance of the increased PTP activity was further supported by confirming it was active against endogenous
tyrosine phosphorylated substrates. Interestingly, phorbol myristate acetate and zymosan, agents which trigger the
macrophage respiratory burst, were found to inhibit the PTP activity of BMM. Our results demonstrate the regulation of
cellular PTP activity by priming agents and further highlight the importance of tyrosine phosphorylation and dephosphoryla-
tion events in the regulation of macrophage function.
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1. Introduction
The macrophage respiratory burst is a normally
dormant metabolic process which, when activated by
the interaction of the macrophage with an appropriate
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stimulus, produces a series of reduced oxygen
metabolites including superoxide, hydrogen peroxide
w xand hydroxyl radicals 1,2 . These products are
utilised by the macrophage to kill ingested micro-
w xorganisms 3 . However, the inappropriate release of
these metabolites may also lead to tissue damage and
w xinflammation 4 .
Activation of the respiratory burst is a two-step
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process involving an initial ‘priming’ phase followed
by a ‘triggering’ event. Priming can be induced in
vitro by exposing macrophages to agents such as
 .bacterial lipopolysaccharide LPS , tumor necrosis
 .factor a TNFa , and granulocytermacrophage-col-
 .ony stimulating factor GMCSF . These agents do not
themselves induce a respiratory burst but rather they
modify the macrophage increasing its responsiveness
to the subsequent triggering stimulus. Thus, trigger-
ing a primed macrophage results in the generation of
a much greater amount of oxygen metabolites as
compared to the response induced by triggering an
w xunprimed macrophage 5 . The biochemical events
underlying the phenomenon of priming are yet to be
fully elucidated, however, it is likely to involve the
amplification of the signal transduction pathways,
allowing a more efficient transmission of the stimula-
tory signals.
A number of laboratories have proposed a critical
 .role for tyrosine kinase s in the activation of the
w xphagocyte respiratory burst 6,7 . Priming
macrophages with LPS or TNFa greatly potentiates
the level of tyrosine phosphorylation associated with
w xthe triggering of the respiratory burst 8,9 and this
may be due, at least in part, to an increase in the
expression andror activity of endogenous tyrosine
w xkinases 10 . However, since the net level of tyrosine
phosphorylation is the result of a balance between
tyrosine kinase activity and the opposing activity of
 .phosphotyrosine phosphatases PTPs , the accumula-
tion of tyrosine phosphorylated proteins might also
be expected to be enhanced by inhibition of PTP
activity. Consistent with this, the treatment of phago-
cytic cells with the PTP inhibitor sodium orthovana-
date, elevates tyrosine phosphorylation and respira-
tory burst activity in response to stimulation
w x8,9,11,12 . We therefore postulated that a potential
mechanism for priming may involve the inhibition of
PTP activity thus enabling a greater accumulation of
tyrosine phosphorylated proteins following activation
 .of a tyrosine kinase s by the triggering stimulus. We
therefore compared the level of PTP activity in primed
and unprimed macrophages. Surprisingly, contrary to
our hypothesis, primed murine bone marrow-derived
 .macrophages BMM demonstrate greatly increased
PTP activity as compared to unprimed cells. How-
ever, the PTP activity of primed cells was reduced
upon stimulating BMM with a triggering agent.
2. Materials and methods
2.1. Reagents
Highly purified recombinant human colony stimu-
 .lating factor CSF-1 , which is biologically cross-re-
w xactive in the murine system 13 , was generously
provided by Chiron Corporation, Emeryville, CA.
Recombinant murine GMCSF was a gift from Dr. A.
Burgess, Ludwig Institute for Cancer Research,
Parkville, Australia. Catalytic subunit of protein ki-
w xnase A purified from bovine heart 14 was kindly
provided by Dr. P. Robinson, John Hunter Hospital,
Newcastle, Australia.
Other reagents were purchased from the following
 .sources: RR-src peptide RRLIEDAEYAARG and
 .human recombinant epidermal growth factor EGF
from Auspep, Melbourne, Australia; LPS purified
from Escherichia coli 0111:B4 by the Westphal
.method from Difco laboratories, Detroit, MI; Re-
combinant murine TNFa , horse heart cytochrome c,
histone type III-S, nonidet P40, phorbol myristate
 .acetate PMA , phenylmethylsulphonyl fluoride
 .  .PMSF , tetramisole, triton X-100 TX100 , sodium
tartrate, sodium orthovanadate and zymosan A from
wSigma Chemical Company, St. Louis, MO; g-
32 x  .P ATP 2000–3000 cpmrpmol from Dupont Aus-
tralia; fetal calf serum from CSL, Parkville, Aus-
tralia; RPMI 1640 and DMEM from Trace Bio-
sciences, Sydney, Australia; ECL Western blotting
detection reagents, Hybond-C nitrocellulose mem-
branes, rainbow molecular weight standards, chemi-
 .luminesence detection film Hyperfilm from Amer-
sham Corporation, Sydney, Australia; AG1X2 anion
exchange resin, AG50WX8 cation exchange resin
and protein assay reagents from Biorad Laboratories,
Richmond, CA; bovine serum albumin and chicken
ovalbumin from Calbiochem Corporation, San Diego,
CA; Aprotinin from Bayer, Pymble, NSW, Australia;
calyculin A from Sapphire Bioscience, Alexandria,
Australia; and affinity-purified murine monoclonal
 .anti-phosphotyrosine antibody PY20 conjugated to
horseradish peroxidase from ICN Biochemicals, Costa
Mesa, CA.
All other chemicals and reagents were of analytical
grade or higher and obtained from standard commer-
cial sources.
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2.2. Cells
Murine BMM were prepared by the culture of
precursor cells, isolated from the bone marrow of
 .Swiss mice and cultured in RPMI 1640, 15% vrv
 .fetal calf serum and 30% vrv L cell-conditioned
medium a crude source of the macrophage-specific
. w xgrowth factor CSF-1 , as previously described 5 .
 .Cells were primed by exposure to LPS 100 ngrml ,
 y9 .  .TNFa 2=10 M , GMCSF 10 ngrml or CSF-1
 .1000 Urml in RPMI-1640, supplemented with 10%
fetal calf serum without L cell-conditioned medium,
 .for 48 h unless otherwise indicated .
A-431 cells human vulval carcinoma cell line of
6 .epidermal origin expressing 10 EGF-receptorsrcell ,
a gift from Dr. Stella Clark, University of Melbourne,
Victoria, Australia, were grown to confluence in
DMEM supplemented with 10% fetal calf serum.
2.3. Preparation of phosphorylated RR-src
The RR-src peptide was phosphorylated on tyro-
sine using the EGF-receptor kinase of A-431 cells in
w 32 xthe presence of g- P ATP as described by Goris et
w xal. 15 . Reactions of 1 ml contained 120 mg A-431
cell membranes, 0.2 mM EGF, 50 mM HEPES pH
.  .  .7.4 , 150 mM NaCl, 0.02% vrv TX100, 5% vrv
glycerol, 2 mM MnCl , 100 mM sodium orthovana-2
w 32 xdate, 1.4 mM RR-src and 250 mM g- P ATP and
were carried out at 308C for 16 h. Radiolabelled
w32 xRR-src was separated from unincorporated P ATP
by anion exchange chromatography using AG1X2
resin. Fractions containing labelled RR-src were
pooled, evaporated to dryness using a Heto lyophyl-
 .izer Radiometer, Australia and resuspended to 100
w xmM in water 16 .
( )2.4. Phosphotyrosine phosphatase PTP acti˝ity
BMM grown in 10 cm2 tissue culture petri dishes
 .Nunc, Roskilde, Denmark were scraped into 50 mM
 .Tris-HCl pH 7.4 containing 150 mM NaCl, 10 mM
aprotinin and 1 mM PMSF and disrupted by sonica-
 tion 5 to 10 s using a Vibra Cell sonicator Sonics
. .and Materials, USA fitted with a micro-probe . Pro-
tein levels in the whole cell sonicate were assessed
using the Biorad protein assay kit Biorad Laborato-
.ries, Richmond, CA, USA with bovine serum albu-
min as a standard. The protein level has previously
w xbeen shown to parallel cell number 17 . In some
experiments the particulate material membrane frac-
.  .tion was separated from the soluble cytosol frac-
tion by centrifugation at 60 000=g, 2 h, 48C, and the
particulate material resuspended to the original vol-
ume in fresh buffer. Unless otherwise stated, 1%
 .vrv TX100 was added to all samples as prelimi-
nary experiments demonstrated this increased the re-
 .covery of PTP activity see Section 3 .
PTP activity was assayed by the dephosphorylation
w32 xof P RR-src peptide as described by Pallen et al.
w x18 . Five microgram of cell lysate protein was incu-
w32 xbated with 2.5mM P RR-src peptide in 30 ml 50
 w xmM MES buffer 2- N-morpholino ethane-sulfonic
.acid, pH 6.0 containing 0.5 mM dithiothreitol for 10
min at 308C. The reaction terminated by the addition
 .of a 10-fold excess volume of 5% wrv trichloro-
w32 xacetic acidr100 mM KHPO and P phosphate re-4
leased quantified by passing each stopped reaction
mixture over a 0.6 ml column of AG50WX8 cation
exchange resin, which was then rinsed twice with 1
ml of water, and the eluent collected and counted in a
w xliquid scintillation counter 19 . Under these condi-
tions, the assay was linear with respect to both incu-
bation time and protein concentration. All assays
were performed in triplicate.
2.5. Dephosphorylation of endogenous substrates
A modification of the method of Ding and Badwey
w x20 was used to assess the ability of cell lysates to
dephosphorylate endogenous macrophage proteins.
LPS-primed BMM were stimulated with zymosan 1
.mgrml, 10 min to elevate endogenous phospho-
w xtyrosine levels 8 . Cells were washed twice in ice-
cold phosphate-buffered saline and lysed in 100 mM
NaCl containing 10 mM Tris-HCl pH 7.2, 2 mM
 .  .EDTA, 0.5% wrv deoxycholate, 1% vrv nonidet
P40, 10 mM MgCl , 1 mM PMSF, 10 mM aprotinin2
and 100 mM sodium orthovanadate, for 15 min on
ice. The protein content of the lysate was determined
by using the Biorad protein assay kit with bovine
serum albumin as a standard. Lysate containing 50
mg of protein was mixed with an equal volume
  .sample buffer 62.5 mM Tris-HCl pH 6.8, 10% vrv
 .  .glycerol, 2% wrv sodium dodecyl sulfate, 5% vrv
 . .2-mercaptoethanol, 0.05% wrv bromophenol blue
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and heated for 5 minutes at 958C. The samples were
subject to sodium dodecyl sulfate polyacrylamide gel
 .electrophoresis 10% gel and electrophoretically
transferred onto nitrocellulose membranes. The im-
mobilised proteins were renatured by incubation in
 .25 mM Tris-HCl pH 7.4 containing 3% wrv gelatin,
137 mM NaCl and 2.7 mM KCl for 1 h at 308C.
 .Membranes were then cut into strips 1 cm wide for
use as immobilised substrate.
Strips of membrane containing immobilised
macrophage proteins were incubated in a 5 ml reac-
 .tion mixture containing 50 mM MES pH 6.0 , 0.5
mgrml dithiothreitol and 200 mg protein of control
or LPS primed lysates for 30 min at room tempera-
ture. Assay buffer was removed and membranes
 .rinsed in Tris-buffered saline pH 7.4 . Remaining
tyrosine phosphorylation was detected using mono-
 .clonal anti-phosphotyrosine antibodies PY20 and
visualized on hyperfilm using a chemiluminescence
detection system. The extent of dephosphorylation
was quantitated using laser densitometry Molecular
.Dynamics Personal Densitometer .
2.6. Dephosphorylation of histone
Histone type III-S was phosphorylated on
serinerthreonine using purified catalytic subunit of
w xprotein kinase A 14 in the presence of 100 mM
w 32 xg- P ATP and 1 mM MgCl for 60 min at 308C.2
w32 xP Histone was separated from free ATP by tri-
chloroacetic acid precipitation. The precipitated mate-
rial was washed twice with 20% trichloroacetic acid
and once with 100% acetone and resuspended to 1.6
 .mgrml in 50 mM Tris buffer pH 7.5 . Histone
dephosphorylation was assayed under identical condi-
tions to the PTP assay described above except that
w32 x160 mgrml P histone was used as substrate. At
the end of the incubation time, the histone was
precipitated with 20% trichloroacetic acid in the pres-
ence of 1 mgrml bovine serum albumin, centrifuged
w32 xand the amount of P phosphate remaining in the
supernate determined using a scintillation counter.
2.7. Respiratory burst
The respiratory bust of adherent macrophages was
assessed by the PMA-induced reduction of cy-
w xtochrome c 5 . The cells, grown in 24-well tissue
culture plates, were incubated in 1 ml of phosphate
buffer 121 mM NaCl, 5 mM KCl, 1.3 mM CaCl ,2
1.2 mM MgSO , 3.1 mM NaH PO , 12.5 mM4 2 4
.Na HPO and 11 mM glucose, pH 7.3 , containing2 4
80 mM cytochrome c with and without 1 mM PMA
for 90 min at 378C. The supernatants were then
collected, the absorbance read at 550 nM. After
removal of the cytochrome c reaction medium, ad-
herent cells were washed with phosphate-buffered
saline and the total protein in each culture well was
determined by the Lowry method using bovine serum
albumin as a standard. The results were expressed as
nmol of cytochrome c reduced per mg of cell protein.
All experiments consisted of triplicate determina-
tions.
3. Results
3.1. Priming agents increase PTP acti˝ity
Total PTP activity of murine BMMs was assessed
by measuring the ability of cell lysates to dephospho-
w32 xrylate P -RR-src peptide. BMMs primed with
TNFa , LPS and GMCSF were found to have signifi-
cantly greater PTP activity as compared to unprimed
 .control BMM. In contrast, pretreatment with CSF-1
 .did not enhance PTP activity Fig. 1 although this
agent was biologically active as evidenced by in-
creased cell proliferation and morphological changes
 .data not shown .
This PTP activity associated with primed BMM
appears to be specific for phosphotyrosine. Under
conditions where lysate from primed BMM exhibited
a 6-fold increase in ability to dephosphorylate RR-src,
the same lysates were unable to dephosphorylate
histone that had been phosphorylated with the ser-
 .inerthreonine kinase, protein kinase A Fig. 2 . Fur-
thermore, dephosphorylation of RR-src by lysates
from primed BMM was not significantly inhibited by
inhibitors of alkaline phosphatase, acid phosphatase
or serinerthreonine phosphatase but was substan-
 .tially inhibited by known inhibitors of PTP Table 1 .
The PTP activity of primed BMM was not signifi-
cantly influenced by the presence of the divalent
cations Ca2q or Mg2q but was significantly inhibited
2q  .by Mn Fig. 3 . The subcellular distribution of PTP
activity in primed BMMs was found predominantly
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Fig. 1. Effect of respiratory burst priming agents on PTP activity
of BMM. BMM were treated for 48 h with tissue culture medium
 .alone control or tissue culture medium containing 10 ngrml
GM-CSF, 2=10y9 M TNFa , 100 ngrml LPS or 1000 Urml
CSF-1. Cell lysates were adjusted to equalise total protein con-
w32 xcentration and assayed for PTP activity using P phosphory-
lated RR-src peptide as substrate. Results are expressed as cpm
 .released and presented as mean"S.E.M. ns7 .
Fig. 2. Substrate specificity of BMM PTP activity. Whole cell
 .  .lysates of control unprimed and LPS-primed 100 ngrml, 48 h
w32BMM were assayed for ability to dephosphorylate P-
x  . w32 x  .SerrThr histone open bars and P-Tyr RR-src hatched bars .
Results are expressed as cpm released and presented as mean"
S.E.M. of triplicate determinations. The experiment shown is
representative of 4 performed.
Table 1
Effect of various phosphatase inhibitors on the PTP activity of
primed BMM a
Inhibitor PTP act. Inhibition
 .  .pmolrmin per mg %
bNo inhibitor 91"4 –
PTP inhibitors:
 .vanadate 1 mM 8"7 98"8
 .molybdate 10 mM 18"5 81"6
Alkaline phosphatase inhibitor:
 .tetramisole 1 mM 87"10 5"9
Acid phosphatase inhibitor:
 .sodium tartrate 5 mM 73"3 19"7
SerrThr phosphatase inhibitor:
 .calyculin A 10 mM 94"15 3"1
a Lysates from TNFa-primed BMM were assayed for PTP activ-
ity in the presence of various known phosphatase inhibitors
w x36–39 .
b Data is presented as mean"S.E.M. of triplicate determinations
and is representative of 3 independent experiments.
 .in the soluble cytosolic fraction, with lesser levels
 .associated with the particulate membrane fraction
 .Fig. 4 . The PTP activity detected in the particulate
Fig. 3. Effect of divalent cations on PTP activity from BMM.
 .Whole cell lysates of LPS-primed 100 ngrml, 48 h BMM were
w32 xassayed for ability to dephosphorylate P phosphorylated RR-
 .  .src peptide in the presence of EGTA 1 mM and EDTA 1 mM
 .plus indicated concentrations of CaCl –B– , MgCl2 2
 .  .PPPv PPP or MnCl –’– . Results are expressed as percent-2
 .age of control EGTArEDTA alone and presented as mean"
 .S.E.M. ns3 . Lack of error bars indicates an error less than the
size of the symbol.
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Fig. 4. Subcellular distribution of PTP activity in BMM. BMM
 .were treated for 48 h with tissue culture medium alone control
or medium containing 100 ngrml LPS. Cells were disrupted by
 .  .sonication lysate and centrifuged 60 000= g, 48C, 2 h . The
 .supernate soluble fraction was collected and the pellet resus-
pended back to the original volume in lysis buffer particulate
.fraction . PTP activity of each fraction was determined using
w32 xP phosphorylated RR-src peptide as substrate. Results are
expressed as cpm released and presented as mean"S.E.M. ns
.3 .
Fig. 5. Effect of TX100 on PTP activity from BMM. BMM were
 .treated for 48 h with tissue culture medium alone control or
medium containing 100 ngrml LPS. Cells were disrupted in the
absence of TX100, divided in two aliquots and TX100 added to
one aliquot at a concentration of 1% vrv. Lysates without open
.  .bars and with hatched bars TX100 were assayed for PTP
w32 xactivity using P phosphorylated RR-src peptide as substrate.
Results are expressed as cpm released and presented as mean"
 .S.E.M. ns7 .
fraction was readily solubilized and was recovered in
the soluble fraction after treatment with 1% TX100.
Furthermore the PTP activity of whole cell lysate was
greatly enhanced with the addition of 1% TX100,
being 2.4"0.1-fold greater in lysate with TX100 as
 .compared to lysate without TX100 ns7, P-0.05 .
This effect of TX100 was observed with both primed
 .and unprimed BMM Fig. 5 and when the soluble
cytosolic fraction alone was used LPS primed cy-
Fig. 6. Time-dependent effects of LPS on PTP and respiratory
burst activity in BMM. BMM were incubated for various lengths
of time in the presence of 100 ngrml LPS. PTP levels using
 .RR-src as the substrate a and respiratory burst in reponse to 1
 .mM PMA b were assessed in replicate cultures. Results are
 .presented as mean"S.E.M. ns4 .
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tosol without TX100s1284"74 cpm; with TX100
.s9536"738 cpm; P-0.01, ns3 .
3.2. Increase of PTP acti˝ity correlates with priming
BMM were exposed to LPS or TNFa for various
times up to 48 h and both PTP activity and superox-
ide production were measured in duplicate cell prepa-
rations. LPS primed BMMs begin to show slightly
elevated PTP activity within 6 h and increases with
 .time to up to 24 h Fig. 6a . Similarly, replicate
BMM cultures show a similar time course for LPS-
induced priming of respiratory burst activity Fig.
.6b . The time course for the TNFa-induced increase
in PTP activity was similar to that of LPS and also
correlated well with priming of the respiratory burst
 .data not shown .
3.3. Triggering agents reduce PTP Acti˝ity
PTP activity was assessed in 48 h LPS primed or
TNFa primed BMMs following triggering with PMA
or zymosan for 10 min. PMA and zymosan did not
effect basal levels of PTP activity in unprimed BMM
Fig. 7. Effect of respiratory burst triggering agents on BMM PTP
activity. BMM were treated for 48 h with tissue culture medium
 . y9alone unprimed or medium containing 2=10 M TNFa . Cells
 .  .were then stimulated with buffer control , PMA 1 mM or
 .zymosan 1 mgrml for 10 min prior to disruption. PTP activity
w32 xin in whole cell lysates was determined using P phosphory-
lated RR-src peptide as substrate. Results are expressed as cpm
 . )released and presented as mean"S.E.M. ns3 . indicates
 .significantly different from control P -0.05 .
Fig. 8. Dephosphorylation of immobilised endogenous substrates.
LPS-primed BMM were stimulated with zymosan in the presence
of vanadate to induce phosphorylation of endogenous proteins
w x8 . The cells were then solubilised and the proteins separated by
PAGE and transferred to nitrocellulose membrane for use as
immobilised substrates. Replicate strips of membrane were incu-
 .bated in 5 ml of buffer alone lane 1 , or buffer containing 200
 .mg fresh lysate of unprimed control; lane 2 or LPS-primed
 .lane 3 BMM for 30 min at 308C. The membranes were then
washed, blocked with bovine serum albuminrovalbumin and the
remaining tyrosine phosphorylation detected with an anti-phos-
 .photyrosine antibody PY20 and visualised using a chemilumi-
nesence detection system. The experiment shown is representa-
tive of 5 performed.
but resulted in a marked inhibition of PTP activity in
 .primed BMM Fig. 7 .
3.4. Dephosphorylation of endogenous proteins
In order to investigate the dephosphorylation of
physiologically relevant substrates, tyrosine phospho-
rylated proteins from zymosan-stimulated BMM were
immobilized on nitrocellulose membranes and ex-
posed to cell lysates as described above. Cell lysates
were able to dephosphorylate the immobilised pro-
teins. Exposure of immobilised proteins to lysates of
LPS-primed BMM resulted in a significantly greater
dephosphorylation than exposure to lysates from un-
primed BMM 50"8% for LPS-primed compared
with 23"11% for unprimed, mean dephosphoryla-
.  .tion "S.E.M., n s 5, P - 0.05 Fig. 8 . The
dephosphorylation of immobilised substrate was
completely inhibited by the presence of 100 mM
 .vanadate data not shown .
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4. Discussion
w32 xUsing the dephosphorylation of the P -RR-src
peptide as a specific assay for phosphotyrosine phos-
phatase activity, we have demonstrated that pretreat-
ment of murine BMM with LPS, TNFa or GMCSF,
but not CSF-1, greatly increases cellular PTP activity
 .Fig. 1 .
It is not clear from our data if the observed
increase in activity is due to the activation of latent
PTP activity already present in the cells, or to the
synthesis of new PTP protein, although the relatively
long time required for this effect might suggest the
latter possibility. Interestingly, the addition of 1%
TX100 to cell lysates increases the PTP activity of
 .both control and primed BMM lysates Fig. 5 . Ini-
tially, it was assumed that this reflected the release of
PTP activity as a result of solubilising the cell mem-
branes. However, the observation that the effect of
TX100 was also observed when added to the soluble
cytosolic fraction suggests that this is not the case.
The fact that a similar fold increase in activity was
observed upon the addition of TX100 to unprimed
cells suggests that the TX100 is enhancing the activ-
 .ity of the PTP s present, perhaps by facilitating the
interaction of the PTP with its substrate.
As the dephosphorylation of exogenously phos-
phorylated artificial substrates such as the RR-src
peptide may not entirely reflect the physiological
activity of endogenous PTPs, we also investigated the
dephosphorylation of endogenously phosphorylated
macrophage proteins. Our results demonstrate that the
LPS-induced enhancement of PTP activity was not
restricted to increased activity toward the RR-src
peptide but that LPS also enhanced the ability of cell
lysates to dephosphorylate a number of endogenous
 .substrates Fig. 8 . Clearly, the overall effect of LPS
on dephosphorylation of endogenous substrates is
proportionally less than that observed with the puri-
fied RR-src substrate, however, this likely reflects
differences in the specificity of the PTP for different
substrates with some endogenous substrates being
dephosphorylated to a greater or lesser extent than
others. Nevertheless, the regulation of BMM PTP
activity by LPS, and other agents, reported here
appears to be physiologically relevant and is likely to
be involved in the regulation of macrophage function.
In this regard, the increase in PTP activity was
found to correlate with priming of the macrophage
respiratory burst. Agents which prime the BMM res-
w xpiratory burst, LPS, TNFa , and GMCSF 5 were all
found to increase PTP activity while CSF-1, which
w xdoes not prime BMM 5,17 , failed to enhance PTP
activity. Furthermore, the time course for increased
PTP activity induced by LPS and TNFa correlated
well with the priming effects of these agents. This
Fig. 9. A hypothesis for the role of PTP in regulating the macrophage respiratory burst. During the priming phase, priming agents such as
 pr imed.LPS or TNFa induce an increase in PTP activity designated PTP which dephosphorylates a regulatory site on an appropriate
tyrosine kinase releasing the regulatory control of this kinase thus ‘priming’ it for enhanced activity. When subsequently exposed to a
triggering stimulus, such as zymosan or PMA, the tyrosine kinase is activated resulting in an accumulation of phosphorylated substrate
 ).and production of a respiratory burst. Opposing the activity of the kinase is a PTP PTP , which may or may not be the same enzyme
as PTP pr imed. The presence of the PTP inhibitor vanadate during the triggering phase inhibits PTP ) preventing the dephosphorylation of
substrate resulting in increased levels of phosphorylated substrate and, consequently, respiratory burst activity.
( )S. Bassal et al.rBiochimica et Biophysica Acta 1355 1997 343–352 351
suggests a role for phosphotyrosine dephosphoryla-
tion in the mechanism of priming. However, such a
suggestion would seem to go against the prevailing
dogma that an increase in tyrosine phosphorylation is
a key event in the activation of the phagocyte respira-
w xtory burst 6,7 . Indeed, we have previously shown
that these priming agents enhance the level of tyro-
sine phosphorylation in BMM stimulated with PMA
or zymosan, and that vanadate, a PTP inhibitor,
w xenhances the respiratory burst response 8,9 .
The answer to these apparent contradictions almost
certainly lies in the complex nature of kinase-phos-
phatase interactions. It is now acknowledged that
PTPs do not simply oppose the action of tyrosine
kinases and that, under some circumstances, the ac-
tion of a PTP can actually lead to increased tyrosine
phosphorylation. The members of the src family of
tyrosine kinases, for example, are negatively regu-
lated by tyrosine phosphorylation and release of this
regulation by dephosphorylation of the kinase results
w xin enhanced kinase activity 21–23 .
We propose that the increased PTP activity associ-
ated with priming which we have designated
pr imed.PTP leads to the dephosphorylation of a regu-
latory site on an appropriate tyrosine kinase releasing
the regulatory control of this kinase and ‘priming’ the
cells for enhanced tyrosine phosphorylation when the
kinase is subsequently activated by a triggering stim-
 .ulus Fig. 9 . The identity of the specific tyrosine
 .kinase s involved has not yet been addressed but,
interestingly, an increase in activity of the src ki-
nases, hck and lyn, associated with priming of the
w xrespiratory burst has previously been reported 10,24
and it is possible that the increase in activity of these
kinases may be directly related to the increase in PTP
activity reported here.
The observation that vanadate, a PTP inhibitor,
w xcan enhance the respiratory burst 8,9,12 is not in-
consistent with our assertion that physiological prim-
ing agents may work through increasing PTP activity.
Vanadate is usually added just prior to triggering of
 .the respiratory burst i.e. after priming has occurred
and presumably acts to amplify the effects of the
 .tyrosine kinase s activated during triggering by pre-
 .venting dephosphorylation of their substrates Fig. 9 .
Consistent with this interpretation, the triggering
agents PMA and zymosan were both found to sup-
 .press cellular PTP activity Fig. 7 , an action which
would serve to help maintain the level of tyrosine
phosphorylation associated with the triggering of the
respiratory burst.
 .The identity of the PTP s responsible for the
increase in PTP activity reported here is not clear.
CD45, which is a receptor-like PTP found primarily
w xin hematopoietic cells 25 , has previously been shown
to be present in the plasma membrane and specific
granules of neutrophils and upregulated on to the cell
surface following stimulation with agents known to
w xactivate the respiratory burst 26–28 . However, the
activity reported above is found predominately in the
 .soluble fraction of the cells Fig. 4 and not in the
particulate fraction as would be expected for CD45.
2q In addition, this activity was inhibited by Mn Fig.
.3 while CD45 has been reported to be activated by
w xthis cation 29 .
 .PTP1C also known as HCP, SHPTP1 or SHP is a
cytosolic PTP that is also expressed predominately in
w xhaematopoietic cells 30–32 . The observation that
levels of PTP1C increase upon differentiation of HL-
w x60 cells into macrophages 32 and that the
macrophage-specific growth factor CSF-1 stimulates
w xthe tyrosine phosphorylation of PTP1C 30 suggests
a possible role for this PTP in the regulation of
macrophage function. However, it is not clear what
contribution, if any, PTP1C makes to the activity
described above. A wide range of cytoplasmic and
w xtransmembrane PTPs have now been identified 33,34
and although those present in the macrophage have
not yet been fully characterised, it is likely that
w xmacrophages will contain multiple PTPs 35 . We are
currently undertaking studies aimed at identifying the
 .specific PTP s upregulated by LPS, TNFa and GM-
CSF in BMM. Similarly, further investigation will be
required to fully understand the precise role this
 .PTP s plays in the mechanisms regulating the
macrophage respiratory burst.
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